<p>Adicet Bio, Inc.（纳斯达克代码：ACET - 免费报告）的股票计划于 12 月 30 日（星期二）进行反向拆分。最近宣布的反向拆分比例为 1 比 16。股东所持股份的数量将在 12 月 29 日（星期一）收盘后进行调整。</p>
<h2>Adicet Bio 股票表现</h2>
<p>在周五的午盘交易中，纳斯达克 ACET 的股票上涨了 $0.00，达到了 $0.52。该公司交易了 2,937,097 股股票，而其平均交易量为 1,112,400 股。该公司的 50 日移动平均价格为 $0.64，200 日移动平均价格为 $0.71。公司的债务与股本比率为 0.01，流动比率为 5.62，速动比率为 5.62。该公司的市值为 7970 万美元，市盈率为 -0.41，贝塔值为 1.61。Adicet Bio 的 52 周低点为 $0.45，52 周高点为 $1.11。</p>
<p>Adicet Bio（纳斯达克代码：ACET - 获取免费报告）最近于 11 月 5 日（星期三）发布了季度财报。公司报告本季度每股收益（EPS）为（$0.29），低于分析师一致预期的（$0.26），差距为（$0.03）。分析师预测，Adicet Bio 本年度将发布 -1.39 的每股收益。</p>
<h2>华尔街分析师观点</h2>
<p>多家研究公司最近对 ACET 发表了看法。花旗集团在 11 月 19 日（星期三）的研究报告中重申了对 Adicet Bio 股票的 “市场表现” 评级。杰富瑞金融集团在 10 月 7 日（星期二）的研究报告中将 Adicet Bio 股票的评级提升至 “强力买入”。Wedbush 在 11 月 6 日（星期四）的研究报告中重申了 “跑赢大盘” 的评级，并对 Adicet Bio 股票设定了 $5.00 的目标价。Weiss Ratings 在 10 月 30 日（星期四）的研究报告中重申了对 Adicet Bio 股票的 “卖出（d-）” 评级。最后，古根海姆在 10 月 8 日（星期三）的研究报告中将 Adicet Bio 股票的目标价从 $7.00 提升至 $8.00，并给予该股票 “买入” 评级。一位股票研究分析师给予该股票 “强力买入” 评级，三位给予 “买入” 评级，两位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat 的数据，Adicet Bio 目前的平均评级为 “适度买入”，共识目标价为 $7.33。</p>
<p><strong>获取我们对 Adicet Bio 的最新分析</strong></p>
<h2>机构投资者对 Adicet Bio 的看法</h2>
<p>多家机构投资者最近对 ACET 的持仓进行了调整。Susquehanna International Group LLP 在第三季度新购入了 Adicet Bio 的股份，价值 $33,000。Citadel Advisors LLC 在第三季度将其在 Adicet Bio 股票中的持股比例提高了 19.8%。Citadel Advisors LLC 目前持有 583,948 股该公司的股票，价值 $473,000，此前在该期间内又购买了 96,342 股。Virtu Financial LLC 在第三季度新购入了 Adicet Bio 的股份，价值约 $65,000。Two Sigma Investments LP 在第三季度将其在 Adicet Bio 股票中的持仓增加了 66.6%。Two Sigma Investments LP 目前持有 854,568 股该公司的股票，价值 $692,000，此前在上个季度又购买了 341,761 股。最后，Squarepoint Ops LLC 在第三季度新购入了 Adicet Bio 的股份，价值约 $38,000。目前 83.89% 的股票由机构投资者和对冲基金持有。</p>
<h2>关于 Adicet Bio</h2>
<p>（获取免费报告）</p>
<p>Adicet Bio, Inc.（纳斯达克：ACET）是一家临床阶段的生物技术公司，专注于开发现成的、同种异体的伽马δ（γδ）T 细胞疗法，用于肿瘤和自身免疫疾病。该公司的专有平台使得能够对γδ T 细胞进行基因工程改造，结合嵌合抗原受体（CARs）和其他分子修饰，以增强肿瘤靶向、扩展和持久性。通过利用γδ T 细胞的固有肿瘤识别特性，Adicet 旨在克服与自体细胞疗法相关的制造和安全挑战。</p>
<p>Adicet 的主要产品候选药物 ADI-001 是一种针对 CD20 的 CAR 工程化同种异体 γδ T 细胞疗法，用于治疗复发或难治性 B 细胞恶性肿瘤。</p>
<h2>特色文章</h2>
<ul>
<li>五只我们更看好的股票，胜过 Adicet Bio</li>
<li>你知道亚马逊计划在 1 月 1 日做什么吗？</li>
<li>开火正式开始……</li>
<li>华盛顿准备开战</li>
<li>你的 “出生权索赔” 刚刚被激活</li>
<li>在 1 月 1 日之前将 $1,000 投入这只股票 [不是 NVDA]</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 $1,000 到 Adicet Bio 吗？</h2>
<p>在你考虑 Adicet Bio 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前立即购买……而 Adicet Bio 并不在名单上。</p>
<p>虽然 Adicet Bio 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

ACET

<p>Adicet Bio, Inc.（纳斯达克代码：ACET）将于 12 月 30 日进行 1 比 16 的反向拆股。股东的持股将在 12 月 29 日市场收盘后进行调整。该公司的股票表现显示当前价格为 0.52 美元，市值为 7970 万美元。分析师对该股票的评级不一，普遍目标价为 7.33 美元。机构投资者持有该股票的 83.89%。Adicet Bio 专注于开发用于肿瘤和自身免疫疾病的异体伽马δ T 细胞疗法</p>

<p>Shares of Adicet Bio, Inc. (NASDAQ:ACET - Free Report) are scheduled to reverse split on Tuesday, December 30th. The 1-16 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Monday, December 29th.</p>
<div class="lb-trans"><p>Adicet Bio, Inc.（纳斯达克代码：ACET - 免费报告）的股票计划于 12 月 30 日（星期二）进行反向拆分。最近宣布的反向拆分比例为 1 比 16。股东所持股份的数量将在 12 月 29 日（星期一）收盘后进行调整。</p>
</div><h2>Adicet Bio Stock Performance</h2>
<div class="lb-trans"><h2>Adicet Bio 股票表现</h2>
</div><p>Shares of NASDAQ ACET traded up $0.00 during mid-day trading on Friday, reaching $0.52. 2,937,097 shares of the company's stock were exchanged, compared to its average volume of 1,112,400. The firm has a 50-day moving average price of $0.64 and a two-hundred day moving average price of $0.71. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.62 and a quick ratio of 5.62. The firm has a market capitalization of $79.70 million, a price-to-earnings ratio of -0.41 and a beta of 1.61. Adicet Bio has a 52 week low of $0.45 and a 52 week high of $1.11.</p>
<div class="lb-trans"><p>在周五的午盘交易中，纳斯达克 ACET 的股票上涨了 $0.00，达到了 $0.52。该公司交易了 2,937,097 股股票，而其平均交易量为 1,112,400 股。该公司的 50 日移动平均价格为 $0.64，200 日移动平均价格为 $0.71。公司的债务与股本比率为 0.01，流动比率为 5.62，速动比率为 5.62。该公司的市值为 7970 万美元，市盈率为 -0.41，贝塔值为 1.61。Adicet Bio 的 52 周低点为 $0.45，52 周高点为 $1.11。</p>
</div><p>Adicet Bio (NASDAQ:ACET - Get Free Report) last posted its quarterly earnings results on Wednesday, November 5th. The company reported ($0.29) EPS for the quarter, missing analysts' consensus estimates of ($0.26) by ($0.03). Analysts predict that Adicet Bio will post -1.39 EPS for the current year.</p>
<div class="lb-trans"><p>Adicet Bio（纳斯达克代码：ACET - 获取免费报告）最近于 11 月 5 日（星期三）发布了季度财报。公司报告本季度每股收益（EPS）为（$0.29），低于分析师一致预期的（$0.26），差距为（$0.03）。分析师预测，Adicet Bio 本年度将发布 -1.39 的每股收益。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>A number of research firms have recently weighed in on ACET. Citigroup reissued a &#34;market perform&#34; rating on shares of Adicet Bio in a research note on Wednesday, November 19th. Jefferies Financial Group raised shares of Adicet Bio to a &#34;strong-buy&#34; rating in a research note on Tuesday, October 7th. Wedbush reaffirmed an &#34;outperform&#34; rating and issued a $5.00 price target on shares of Adicet Bio in a research note on Thursday, November 6th. Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Adicet Bio in a research note on Thursday, October 30th. Finally, Guggenheim boosted their price objective on shares of Adicet Bio from $7.00 to $8.00 and gave the stock a &#34;buy&#34; rating in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Adicet Bio presently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $7.33.</p>
<div class="lb-trans"><p>多家研究公司最近对 ACET 发表了看法。花旗集团在 11 月 19 日（星期三）的研究报告中重申了对 Adicet Bio 股票的 “市场表现” 评级。杰富瑞金融集团在 10 月 7 日（星期二）的研究报告中将 Adicet Bio 股票的评级提升至 “强力买入”。Wedbush 在 11 月 6 日（星期四）的研究报告中重申了 “跑赢大盘” 的评级，并对 Adicet Bio 股票设定了 $5.00 的目标价。Weiss Ratings 在 10 月 30 日（星期四）的研究报告中重申了对 Adicet Bio 股票的 “卖出（d-）” 评级。最后，古根海姆在 10 月 8 日（星期三）的研究报告中将 Adicet Bio 股票的目标价从 $7.00 提升至 $8.00，并给予该股票 “买入” 评级。一位股票研究分析师给予该股票 “强力买入” 评级，三位给予 “买入” 评级，两位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat 的数据，Adicet Bio 目前的平均评级为 “适度买入”，共识目标价为 $7.33。</p>
</div><p><strong>Get Our Latest Analysis on Adicet Bio</strong></p>
<div class="lb-trans"><p><strong>获取我们对 Adicet Bio 的最新分析</strong></p>
</div><h2>Institutional Investors Weigh In On Adicet Bio</h2>
<div class="lb-trans"><h2>机构投资者对 Adicet Bio 的看法</h2>
</div><p>A number of institutional investors have recently made changes to their positions in ACET. Susquehanna International Group LLP acquired a new position in Adicet Bio during the 3rd quarter worth $33,000. Citadel Advisors LLC boosted its stake in shares of Adicet Bio by 19.8% in the 3rd quarter. Citadel Advisors LLC now owns 583,948 shares of the company's stock valued at $473,000 after buying an additional 96,342 shares during the period. Virtu Financial LLC acquired a new position in shares of Adicet Bio during the third quarter worth about $65,000. Two Sigma Investments LP grew its position in shares of Adicet Bio by 66.6% during the third quarter. Two Sigma Investments LP now owns 854,568 shares of the company's stock worth $692,000 after buying an additional 341,761 shares in the last quarter. Finally, Squarepoint Ops LLC purchased a new stake in shares of Adicet Bio during the third quarter worth approximately $38,000. 83.89% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>多家机构投资者最近对 ACET 的持仓进行了调整。Susquehanna International Group LLP 在第三季度新购入了 Adicet Bio 的股份，价值 $33,000。Citadel Advisors LLC 在第三季度将其在 Adicet Bio 股票中的持股比例提高了 19.8%。Citadel Advisors LLC 目前持有 583,948 股该公司的股票，价值 $473,000，此前在该期间内又购买了 96,342 股。Virtu Financial LLC 在第三季度新购入了 Adicet Bio 的股份，价值约 $65,000。Two Sigma Investments LP 在第三季度将其在 Adicet Bio 股票中的持仓增加了 66.6%。Two Sigma Investments LP 目前持有 854,568 股该公司的股票，价值 $692,000，此前在上个季度又购买了 341,761 股。最后，Squarepoint Ops LLC 在第三季度新购入了 Adicet Bio 的股份，价值约 $38,000。目前 83.89% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>About Adicet Bio</h2>
<div class="lb-trans"><h2>关于 Adicet Bio</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Adicet Bio, Inc NASDAQ: ACET is a clinical‐stage biotechnology company specializing in the development of off‐the‐shelf, allogeneic gamma delta (γδ) T cell therapies for oncology and autoimmune disorders. The company's proprietary platform enables the genetic engineering of γδ T cells with chimeric antigen receptors (CARs) and other molecular modifications to enhance tumor targeting, expansion, and persistence. By leveraging the innate tumor-recognition properties of γδ T cells, Adicet seeks to overcome the manufacturing and safety challenges associated with autologous cell therapies.</p>
<div class="lb-trans"><p>Adicet Bio, Inc.（纳斯达克：ACET）是一家临床阶段的生物技术公司，专注于开发现成的、同种异体的伽马δ（γδ）T 细胞疗法，用于肿瘤和自身免疫疾病。该公司的专有平台使得能够对γδ T 细胞进行基因工程改造，结合嵌合抗原受体（CARs）和其他分子修饰，以增强肿瘤靶向、扩展和持久性。通过利用γδ T 细胞的固有肿瘤识别特性，Adicet 旨在克服与自体细胞疗法相关的制造和安全挑战。</p>
</div><p>Adicet's lead product candidate, ADI-001, is a CAR‐engineered allogeneic γδ T cell therapy directed against CD20 for the treatment of relapsed or refractory B-cell malignancies.</p>
<div class="lb-trans"><p>Adicet 的主要产品候选药物 ADI-001 是一种针对 CD20 的 CAR 工程化同种异体 γδ T 细胞疗法，用于治疗复发或难治性 B 细胞恶性肿瘤。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>特色文章</h2>
</div><ul>
<li>Five stocks we like better than Adicet Bio</li>
<li>Do you know what Amazon is planning for January 1?</li>
<li>Shots officially fired…</li>
<li>Washington prepares for war</li>
<li>Your “birthright claim” just got activated</li>
<li>Put $1,000 into this stock by Jan 1 [Not NVDA]</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Adicet Bio</li>
<li>你知道亚马逊计划在 1 月 1 日做什么吗？</li>
<li>开火正式开始……</li>
<li>华盛顿准备开战</li>
<li>你的 “出生权索赔” 刚刚被激活</li>
<li>在 1 月 1 日之前将 $1,000 投入这只股票 [不是 NVDA]</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Adicet Bio Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 $1,000 到 Adicet Bio 吗？</h2>
</div><p>Before you consider Adicet Bio, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Adicet Bio 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Adicet Bio wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前立即购买……而 Adicet Bio 并不在名单上。</p>
</div><p>While Adicet Bio currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Adicet Bio 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Adicet Bio 股票计划于 12 月 30 日星期二进行反向拆股（NASDAQ:ACET）